Literature DB >> 14766318

Retinal ischemia: mechanisms of damage and potential therapeutic strategies.

Neville N Osborne1, Robert J Casson, John P M Wood, Glyn Chidlow, Mark Graham, José Melena.   

Abstract

Retinal ischemia is a common cause of visual impairment and blindness. At the cellular level, ischemic retinal injury consists of a self-reinforcing destructive cascade involving neuronal depolarisation, calcium influx and oxidative stress initiated by energy failure and increased glutamatergic stimulation. There is a cell-specific sensitivity to ischemic injury which may reflect variability in the balance of excitatory and inhibitory neurotransmitter receptors on a given cell. A number of animal models and analytical techniques have been used to study retinal ischemia, and an increasing number of treatments have been shown to interrupt the "ischemic cascade" and attenuate the detrimental effects of retinal ischemia. Thus far, however, success in the laboratory has not been translated to the clinic. Difficulties with the route of administration, dosage, and adverse effects may render certain experimental treatments clinically unusable. Furthermore, neuroprotection-based treatment strategies for stroke have so far been disappointing. However, compared to the brain, the retina exhibits a remarkable natural resistance to ischemic injury, which may reflect its peculiar metabolism and unique environment. Given the increasing understanding of the events involved in ischemic neuronal injury it is hoped that clinically effective treatments for retinal ischemia will soon be available.

Entities:  

Mesh:

Year:  2004        PMID: 14766318     DOI: 10.1016/j.preteyeres.2003.12.001

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  311 in total

1.  Neuroglobin protection in retinal ischemia.

Authors:  Anita S Y Chan; Sindhu Saraswathy; Matus Rehak; Mari Ueki; Narsing A Rao
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-13       Impact factor: 4.799

2.  Is there any association between primary hyperparathyroidism and ocular changes, such as central corneal thickness, retinal thickness, and intraocular pressure?

Authors:  Husniye Baser; Neslihan Cuhaci; Oya Topaloglu; Fatma Yulek; Nagihan Ugurlu; Reyhan Ersoy; Nurullah Cagil; Bekir Cakir
Journal:  Endocrine       Date:  2015-08-29       Impact factor: 3.633

3.  Progressive degeneration of retinal and superior collicular functions in mice with sustained ocular hypertension.

Authors:  Hui Chen; Yan Zhao; Mingna Liu; Liang Feng; Zhen Puyang; Ji Yi; Peiji Liang; Hao F Zhang; Jianhua Cang; John B Troy; Xiaorong Liu
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-02-26       Impact factor: 4.799

4.  Opioid receptor activation: suppression of ischemia/reperfusion-induced production of TNF-α in the retina.

Authors:  Shahid Husain; Gregory I Liou; Craig E Crosson
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-20       Impact factor: 4.799

5.  Degree of damage compensation by various PACAP treatments in monosodium glutamate-induced retinal degeneration.

Authors:  Norbert Babai; Tamás Atlasz; Andrea Tamás; Dóra Reglödi; Gábor Tóth; Péter Kiss; Róbert Gábriel
Journal:  Neurotox Res       Date:  2005-11       Impact factor: 3.911

6.  Retinal ion regulation in a mouse model of diabetic retinopathy: natural history and the effect of Cu/Zn superoxide dismutase overexpression.

Authors:  Bruce A Berkowitz; Marius Gradianu; David Bissig; Timothy S Kern; Robin Roberts
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-12-13       Impact factor: 4.799

7.  Long-term effects of neonatal hypoxia-ischemia on structural and physiological integrity of the eye and visual pathway by multimodal MRI.

Authors:  Kevin C Chan; Swarupa Kancherla; Shu-Juan Fan; Ed X Wu
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-09       Impact factor: 4.799

8.  Modulation of voltage-gated Ca2+ channels in rat retinal ganglion cells by gabapentin.

Authors:  Spring R Farrell; Allison Sargoy; Nicholas C Brecha; Steven Barnes
Journal:  Vis Neurosci       Date:  2014-01       Impact factor: 3.241

9.  Baicalein protects against retinal ischemia by antioxidation, antiapoptosis, downregulation of HIF-1α, VEGF, and MMP-9 and upregulation of HO-1.

Authors:  Hsiao-Ming Chao; Min-Jay Chuang; Jorn-Hon Liu; Xiao-Qian Liu; Li-Kang Ho; Wynn H T Pan; Xiu-Mei Zhang; Chi-Ming Liu; Shen-Kou Tsai; Chi-Woon Kong; Shou-Dong Lee; Mi-Mi Chen; Fang-Ping Chao
Journal:  J Ocul Pharmacol Ther       Date:  2013-03-28       Impact factor: 2.671

10.  Virally delivered, constitutively active NFκB improves survival of injured retinal ganglion cells.

Authors:  Galina Dvoriantchikova; Steve Pappas; Xueting Luo; Marcio Ribeiro; Dagmara Danek; Daniel Pelaez; Kevin K Park; Dmitry Ivanov
Journal:  Eur J Neurosci       Date:  2016-09-13       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.